Mode
Text Size
Log in / Sign up
Phase 3 N=363 Randomized Double-blind Treatment

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Enrolled (actual)
363
Serious AEs
1.7%
Results posted
Jun 2015
Primary outcome: Primary: Percentage of Participants With a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade Response — 59.2; 65.3; 23.0 percentage of participants — p=<0.001

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Deoxycholic acid injection (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Kythera Biopharmaceuticals
Primary completion
Jan 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade Response
59.2; 65.3; 23.0 <0.001 sig
PRIMARY
Percentage of Participants With a Subject Self Rating Scale (SSRS) Response
53.3; 66.1; 28.7 <0.001 sig
SECONDARY
Percentage of Participants With a CR-SMFRS 2-grade Response
9.2; 17.4; 1.6 0.028 sig
SECONDARY
Change From Baseline in CR-SMFRS Scores
-0.7; -0.9; -0.2 <0.001 sig
SECONDARY
Change From Baseline in SSRS Scores
2.4; 2.8; 1.4 <0.001 sig
SECONDARY
Change From Baseline in Submental Fat Thickness
-3.8; -4.2; -1.7 <0.001 sig
SECONDARY
Change From Baseline in Patient-reported Submental Fat Rating Scale (PR-SMFRS)
67.0; 73.6; 32.4; 32.0; 22.6; 59.3 <0.001 sig
SECONDARY
Change From Baseline in Patient-Reported Submental Fat Impact Scale (PR-SMFIS)
SECONDARY
Change From Baseline in Self-rating of Attractiveness
0.9; 0.5; 0.3; 1.8; 1.9; 0.5
SECONDARY
Change From Baseline in Derriford Appearance Scale 24 (DAS24)
SECONDARY
Change From Baseline in Body Image Quality of Life Inventory (BIQLI)

Summary

To evaluate the safety and efficacy of deoxycholic acid injection in the reduction of submental fat (fat below the chin).

Eligibility Criteria

Inclusion Criteria

  • Submental fat graded by the investigator as 2 or 3 using the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) as determined on Visit 2.
  • Dissatisfaction with the submental area rated by the subject as 0, 1, 2, or 3 using the Subject Self Rating Scale (SSRS).
  • Males and nonpregnant, nonlactating females between 18 and 65 years of age, inclusive on the day of randomization. Females of childbearing potential must have a negative human chorionic gonadotropin (hCG) test result within 28 days before randomization and agree to practice medically acceptable birth control during the course of the study. Medically acceptable birth control includes: surgical sterilization, hormonal contraceptives, barrier methods or an intrauterine device (IUD).
  • History of stable body weight, in the judgment of the investigator, for at least 6 months before randomization. No significant change, in the judgment of the investigator, in diet or exercise practices for at least 6 months before randomization and agreement to not change diet or exercise practices during the course of the study.
  • Expected to comply with and understand the visit schedule and all protocol-specified tests and procedures.
  • Medically able to undergo the administration of study material determined by clinical evaluations made within 56 days before and laboratory tests obtained within 28 days before randomization for which the investigator identified no clinically significant abnormality.
  • Signed informed consent obtained before any study-specific procedure is performed.

Exclusion Criteria

  • History of any intervention to treat submental fat (e.g., liposuction, surgery, or lipolytic agents) or trauma associated with the chin or neck areas, which in the judgment of the investigator may affect evaluation of safety or efficacy of treatment.
  • Loose skin in the neck or chin area for which reduction in submental fat may, in the judgment of the investigator, result in an aesthetically unacceptable outcome or a score of 4 on the Skin Laxity Rating Scale (SLRS).
  • Prominent platysmal bands at rest or other anatomical features that, in the judgment of the investigator, may interfere with the evaluation of submental fat or result in an aesthetically unacceptable outcome.
  • Evidence of any cause of enlargement in the submental area (e.g., thyroid enlargement or cervical adenopathy) other than localized submental fat.
  • Body mass index (BMI) greater than 30.
  • Currently on or considering starting a weight reduction regimen.
  • Any medical condition (e.g., respiratory, cardiovascular, hepatic, neurological disease, uncontrolled hypertension, or thyroid dysfunction) that would interfere with assessment of safety or efficacy or compromise the subject's ability to undergo study procedures or provide informed consent.
  • Treatment with radio frequency, laser procedures, chemical peels, or dermal fillers in the neck or chin area within 12 months before randomization, or botulinum toxin injections in the neck or chin area within 6 months before randomization.
  • History of sensitivity to any components of the study material or to topical or local anesthetics (e.g., lidocaine, benzocaine, or novocaine).
  • Previous randomization into this study or previous treatment with ATX-101.
  • Treatment with an investigational device or agent within 30 days of randomization.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01305577). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search